Sustainability

Overview

Maravai is committed to environmentally and socially responsible growth. We recognize that acting with a sustainability mindset is critical to serving our stakeholders, including our team members, investors, customers, supplier partners, and the communities where we live and work. Our commitment to sustainability is enterprise-wide and connects every individual across our organization.

Maravai is the old Bolognese Italian word for “miracle.” Our name symbolizes our belief in the phenomenal power of critical thinking, steadfast rigor, unwavering attention to detail, and perseverance. These are hallmarks of scientific innovation and a sustainable business. Sustainability practices are essential to enabling the extraordinary science that delivers everyday miracles.

View Leadership team View Board of Directors

Our 2024 Sustainability Report

Beginning with our inaugural report for 2021, we committed to sharing our sustainability performance annually. This report outlines our core initiatives and performance metrics for the 2024 fiscal year.

Contact: sustainability@maravai.com

View our sustainability report

Our Sustainability Framework

Sustainability oversight

Primary oversight of our sustainability strategy and related risks is managed by the Nominating, Governance, and Risk (NGR) Committee of our Board of Directors (the Board). Responsibilities for sustainability factors across our organization are defined at Board, Nominating, Governance, and Risk Committee, and management levels. Implementing those responsibilities is shared across departments and portfolio businesses.

Our sustainability priorities

Our sustainability framework informs our strategy and guides our approach to managing risks and opportunities to achieve sustainable growth. Our framework focuses on the following key pillars: Product innovation, Our people, Governance leadership, and Sustainable growth.

We continue to build upon the learnings from our 2023 stakeholder assessment, which identified and prioritized the sustainability issues that are most important to our company and stakeholders.

Product innovation

Expanding the possibilities of genomic medicine

Our mission—to enable the miracles of science for the next generation of medicines—remains our driving force. Our customers worldwide rely on our critical products and services as essential components in developing life-changing medicines, vaccines, and diagnostics. We are committed to advancing human health by expanding our technological capabilities, enhancing our product offerings, and supporting our customers' innovations. We actively participate in shaping the future of biotechnology.

  • Shipped over 2,900 distinct products designed to support lifechanging medicines and diagnostics.
  • 136 – Active clinical programs by CleanCap® customers as of December 31, 2024: 43% in Phase 1, 43% in Phase 2 and 14% in Phase 3/4.
  • ~400 – Preclinical programs in the drug development pipeline utilizing CleanCap® technology.
  • 49 – New product introductions from Maravai portfolio companies during 2024.
  • M6 – CleanCap® M6 analog, the newest cap analog in the CleanCap® portfolio is now available at GMP quality.
  • Cygnus Technologies now offers 25 expression systems with more than 30 different kits.
  • 4 IVT enzymes – Through the Alphazyme acquisition, we have added critical IVT enzyme manufacturing capabilities to Maravai’s Nucleic Acid Production Segment.
  • 130+ GMP batches for mRNA have been manufactured by TriLink BioTechnologies.
  • Over 400 suppliers are in the Maravai network, and greater than 95% of our Tier 1 supply chain is U.S. based.

Our people

Expanding our possibilities for our employees

Our people drive Maravai’s mission to enable the miracles of science. We are committed to fostering a safe, healthy, and inclusive environment where every employee feels valued, supported, and empowered to achieve their full potential.

  • Our employee engagement survey participation rate was 95%. The survey received over 2,600 comments.
  • We expanded the structure and focus of our ERG to facilitate advocacy, mentorship, and outreach across Maravai.
  • Nearly all our employees completed annual workplace diversity, inclusion, and sensitivity training in 2024.
  • Our employees completed 561 voluntary, non-compliance training courses throughout 2024.
  • Employees volunteered their time using an Impact Day and donated about 800 hours of community service in 2024.
  • In 2024, employee contributions of approximately $14,000 to non-profit organizations were matched by Maravai.

Governance leadership

Expanding possibilities through good corporate governance

We believe ensuring effective corporate governance helps build business resilience. Robust corporate governance practices are fundamental to Maravai’s long-term success and sustainability. Our governance framework ensures clear Board visibility into significant risks and opportunities, including those related to sustainability matters, as outlined in our Corporate Governance Guidelines.

  • Appointed an independent Chairman of the Board.
  • 100% of the standing Committees of our Board are chaired by independent board members and two of our Committees are chaired by women.
  • Rolled out new program with dedicated ethics liaisons at each company site.
  • A new facility manufacturing small molecules, including CleanCap® technology, began manufacturing in 2024 to spread risk and support the U.S. government in future pandemic preparedness.

Sustainable growth

Expanding possibilities to protect the planet

We embrace the role we play in enabling our customers to create medicines that will improve lives all over the world. As part of our commitment to improve human health, we take pride in our efforts to protect the health of the planet for future generations. Our approach to environmental stewardship involves a combination of sustainability strategies, such as reducing our emissions, waste, water, and energy use while continuously improving our data management processes and reporting practices.

  • Enhanced our GHG emissions data collection and disclosure of Scope 3 emissions.
  • At our Cygnus Technologies facility in Leland, solar panels were installed in 2023 and offset some of the site’s energy use in 2024.
  • Many of our sites are using biodegradable plastic bags for shipping and other processes.
  • Glen Research initiated a nitrile glove recycling program with PolyCarbin that diverts used nitrile gloves from landfills and repurposes them into consumer goods.

Document Library

Reporting

Environmental documents

Social documents

Governance documents